Onconova reports Q3 net loss $5.4M; plans Phase 1/2a narazaciclib trial in endometrial cancer in 1Q23

Traws Pharma, Inc.

2022-Q3 EPS reported -$0.65 revenue$170,000

Net loss of $5.4M ($0.26/share) vs $3.5M ($0.22) in Q3 2021; R&D expenses rose to $3.6M from $1.8M.
Cash and equivalents $42.6M as of Sep 30, 2022, down from $55.1M at Dec 31, 2021; expects to fund operations into 2024.
Plans to initiate Phase 1/2a trial of narazaciclib + letrozole in recurrent LGEEC in 1Q23; preliminary data expected 4Q23.
Rigosertib/nivolumab trial in KRAS-mutated NSCLC showed one complete response and two partial responses in 14 evaluable patients.
Rigosertib investigator-sponsored trials continue; Phase 2 melanoma trial on track for initiation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Traws Pharma, Inc. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 14, 2022, Onconova Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

Traws Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-118575

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.